Treatment with Sulfatide or its Precursor, Galactosylceramide, Prevents Diabetes in NOD Mice

References

• Buschard K, Josefsen K, Horn T, Fredman P. Sulphatide and sulphatide antibodies in insulin-dependent diabetes mellitus. Lancet 1993; 342: 840
   PubMed Web of Science ®Google Scholar
• Vos J P, Lopes-Cardozo M, Gadella B M. Metabolic and functional aspects of sulfo-galactolipids. Biochim Biophys Acta 1994; 1211: 125–149
   PubMed Web of Science ®Google Scholar
• Buschard K, Josefsen K, Hansen S V, Horn T, Marshall M O, Persson H, Mansson J E, Fredman P. Sulphatide in islets of Langerhans and in organs affected in diabetic late complications: a study in human and animal tissue. Diabetologia 1994; 37: 1000–1006
   PubMed Web of Science ®Google Scholar
• Buschard K, Horn T, Aaen K, Josefsen K, Persson H, Fred-Man P. Presence of sulphatide (3′-sulphogalactosylceramide) in pericytes in the choroid layer of the eye: sharing of this glycolipid autoantigen with islets of Langerhans. Diabetologia 1996; 39: 658–666
   PubMed Web of Science ®Google Scholar
• Buschard K, Hageman I, Kornerup Hansen A, Fredman P. Neonatal treatment of DP-BB rats with sulphatide delays development of diabetes but does not change incidence. APMIS 1995; 103: 193–196
   PubMed Web of Science ®Google Scholar
• Svennerholm L, Fredman P. A procedure for the quantitative isolation of brain ganglioside. Biochim Biophys Acta 1980; 617: 97–109
   PubMed Web of Science ®Google Scholar
• Månsson J E, Mo H, Egge H, Svennerholm L. Trisialosyllac-tosylceramide (GT3) is a ganglioside of human lung. FEBS Lett 1986; 196: 259–262
   PubMed Web of Science ®Google Scholar
• Buschard K, Schloot N C, Kaas A, Bock T, Horn T, Fredman P, Roep B O. Immunomodulation of insulin-specific autoreactive T-cells by sulfatide which is variably expressed in beta cells. Diabetologia 1999; 42: 1212–1218
   PubMed Web of Science ®Google Scholar
• Reich E P, von Grafenstein H, Barlow A, Swenson K E, Williams K, Janeway C. A., Jr. Self peptides isolated from MHC glycoproteins of non-obese diabetic mice. J Immunol 1994; 52: 2279–2288
   Google Scholar
• Gallichan W S, Balasa B, Davies J D, Sarvetnick N. Pancreatic IL-4 expression results in islets-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J Immunol 1999; 163: 1696–1703
   PubMed Web of Science ®Google Scholar
• Dunsavage M B, O'Leary C J, Baumgart T G, Solvason N, Howard M, Lafferty K, Deshpande S, Reich E P. A confor-mationally-constrained MHC class II I-Ag7-derived peptide protects NOD mice from the development of diabetes. J Autoimmun 1999; 12: 233–242
   PubMed Web of Science ®Google Scholar
• Gotfredsen C, Buschard K, Frandsen E. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 1985; 28: 933–935
   PubMed Web of Science ®Google Scholar
• Atkinson M A, Maclaren N K, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990; 39: 933–937
   PubMed Web of Science ®Google Scholar
• Bowman M A, Campbell L, Darrow B L, Ellis T M, Suresh A, Atkinson M A. Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM. Diabetes 1996; 45: 205–208
   PubMed Web of Science ®Google Scholar
• Kaufman D L, Clare-Salzler M, Tian J, Forsthuber T, Ting G SP, Robinson P, Atkinson M A, Sercarz E E, Tobin A J, Leh-Mann P. V. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366: 69–72
   PubMed Web of Science ®Google Scholar
• Tisch R, Yang X D, Singer S M, Liblau R S, Fugger L, McDevitt H O. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366: 72–75
   PubMed Web of Science ®Google Scholar
• Ramiya V K, Lan M S, Wasserfall C H, Notkins A L, Maclaren N K. Immunization therapies in the prevention of diabetes. J Autoimmun 1997; 10: 287–292
   PubMed Web of Science ®Google Scholar
• Atkinson M A, Leiter E H. The NOD mouse model of type 1 diabetes: as good as it gets. Nat Med 1999; 5: 601–604
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway C. A., Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91: 295–298
   PubMed Web of Science ®Google Scholar
• Porcelli S A, Morita C T, Modlin R L. T-cell recognition of non-peptide antigens. Curr Opin Immunol 1996; 8: 510–516
   PubMed Web of Science ®Google Scholar
• Funda D, Stenvang J P, Buschard K. Age-related changes in Tγö cells of NOD mice. Immunology Letters 1995; 45: 179–184
   PubMed Web of Science ®Google Scholar
• Zeng Z H, Castano A R, Segelke B W, Stura E A, Peterson P A, Wilson I A. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 1997; 277: 339–345
   PubMed Web of Science ®Google Scholar
• Jackman R M, Stenger S, Lee A, Moody D B, Rogers R A, Niazi K R, Sugita M, Modlin R L, Peters P J, Porcelli S A. The tyrosine-containing cytoplasmic tail of CDlb is essential for its efficient presentation of bacterial lipid antigens. Immunity 1998; 8: 341–351
   PubMed Web of Science ®Google Scholar
• Ernst W A, Maher J, Cho S, Niazi K R, Chatterjee D, Moody D B, Besra G S, Watanabe Y, Jensen P E, Porcelli S A, Kro-Nenberg M., Modlin R L. Molecular interaction of CDlb with lipoglycan antigens. Immunity 1998; 8: 331–340
   PubMed Web of Science ®Google Scholar
• Joyce S, Woods A S, Yewdell J W, Bennink J R, de Silva A D, Boesteanu A, Balk S P, Cotter R J, Brutkiewicz R R. Natural ligand of mouse CD ldl: cellular glycosyl-phosphatidylinosi-tol. Science 1998; 279: 1541–1544
   PubMed Web of Science ®Google Scholar
• Kawano T, Junqing C, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Kosek H, Taniguchi M. CD Id-restricted and TCR-mediated activation of Vαl4 NKT cells by glycosylceramides. Science 1997; 278: 1626–1629
   PubMed Web of Science ®Google Scholar
• Chen H, Paul W E. Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN-γ upon activation by anti-CD3 or CD1. J Immunol 1997; 159: 2240–2249
   PubMed Web of Science ®Google Scholar
• Gombert J M, Herbelin A, Tancrede-Bohin E, Dy M, Char-Naud C., Bach J F. Early quantitative and functional deficiency of NKl+-like thymocytes in the NOD mouse. Eur J Immunol 1996; 26: 2989–2998
   PubMed Web of Science ®Google Scholar
• Kukreja A, Sun Z S, Chen Q Y, Vargas A, Chalew S, Gomez R, Maclaren N K. Altered regulatory functions of T cells associated with NK-T cell deficiency in immune mediated (type 1) diabetes. Diabetes 2000; 49(suppl 1)A36
   Google Scholar
• Lehuen A, Lantz O, Beaudoin L, Laloux V, Carnaud C, Ben-Delac A., Bach J F, Monteiro R C. Overexpression of natural killer T cells protects Vα14-Jα281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998; 188: 1831–1839
   PubMed Web of Science ®Google Scholar
• Atkinson M A, Maclaren N K, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990; 39: 933–937
   PubMed Web of Science ®Google Scholar